September 14, 3:58 AM
Gainers Akero Therapeutics, Inc. (NASDAQ: AKRO) shares jumped 136.8% to settle at $29.05 on Tuesday after the company's Phase 2b HARMONY study met its primary endpoint for both the 50mg and 28mg EFX dose groups.
September 13, 8:49 AM
BOULDER, Colo.--(BUSINESS WIRE)-- Edgewise Therapeutics, Inc., (NASDAQ:EWTX) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering of $100 million of its common
Edgewise Therapeutics Announced 4-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy; Announced Significant Decrease in Levels of Serum Creatine Kinase and Fast Skeletal Muscle Troponin I
September 11, 6:01 PM
– Remarkable North Star Ambulatory Assessment scale (NSAA) improvements relative to BMD natural history trajectories – – Significant decrease in levels of serum creatine kinase (CK) and fast skeletal muscle troponin I (TNNI2), enzyme biomarkers strongly associated with muscle damage caused by BMD – – EDG-5506 continues to be well-tolerated with no serious adverse events observed –
August 25, 5:14 AM
Goldman Sachs analyst Madhu Kumar downgrades Edgewise Therapeutics (NASDAQ:EWTX) from Neutral to Sell and announces $5 price target.
June 21, 8:47 AM
Edgewise Therapeutics Inc (NASDAQ:EWTX) announced 2-month interim results from the ARCH study of EDG-5506 in adults with Becker Muscular Dystrophy (BMD). …
May 12, 2:10 PM
Over the past 3 months, 4 analysts have published their opinion on Edgewise Therapeutics (NASDAQ:EWTX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.